Literature DB >> 25245772

Protection conferred by recombinant turkey herpesvirus avian influenza (rHVT-H5) vaccine in the rearing period in two commercial layer chicken breeds in Egypt.

Walid Kilany1, Gwenaelle Dauphin, Abdullah Selim, Astrid Tripodi, Mohamed Samy, Heba Sobhy, Sophie VonDobschuetz, Marwa Safwat, Mona Saad, Ahmed Erfan, Mohamed Hassan, Juan Lubroth, Yilma Jobre.   

Abstract

The effectiveness of recombinant turkey herpesvirus avian influenza (A/swan/Hungary/4999/2006(H5N1)) clade 2.2 virus (rHVT-H5) vaccine was evaluated in two layer chicken breeds (White Bovans [WB] and Brown Shaver [BS]). One dose of rHVT-H5 vaccine was administered at day 1 and birds were monitored serologically (haemagglutination inhibition test) and virologically for 19 weeks. Maternally-derived antibody and post-vaccination H5 antibody titres were measured using the Chinese (A/Goose/Guangdong/1/96(H5N1)) HA and the Egyptian (A/chicken/Egypt/128s/2012(H5N1)) HA as antigens. The challenge was conducted at 19 weeks of age and on six experimental groups: Groups I (WB) and II (BS), both vaccinated and challenged; Groups III (WB) and IV (BS), both vaccinated but not challenged; Groups V and VI, unvaccinated specific pathogen free chickens, serving respectively as positive and negative controls. The challenge virus was the clade 2.2.1 highly pathogenic avian influenza H5N1 A/chicken/Egypt/128s/2012 at a dose of 10(6) median embryo infective dose. For both breeds, complete maternally-derived antibody waning occurred at the age of 4 weeks. The immune response to rHVT-H5 vaccination was detected from the sixth week. The seroconversion rates for both breeds reached 85.7 to 100% in the eighth week of age. Protection levels of 73.3%, 60% and 0% were respectively recorded in Groups I, II and V. No mortalities occurred in the unchallenged groups. Group I showed superior results for all measured post-challenge parameters. In conclusion, a single rHVT-H5 hatchery vaccination conferred a high level of protection for a relatively extended period. This vaccine could be an important tool for future A/H5N1 prevention/control in endemic countries. Further studies on persistence of immunity beyond 19 weeks, need for booster with inactivated vaccines, breed susceptibility and vaccinal response, and transmissibility are recommended.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245772     DOI: 10.1080/03079457.2014.966302

Source DB:  PubMed          Journal:  Avian Pathol        ISSN: 0307-9457            Impact factor:   3.378


  4 in total

1.  Effectiveness of different avian influenza (H5) vaccination regimens in layer chickens on the humoral immune response and interferon-alpha signalling immune marker.

Authors:  Mustafa Hamad; Omar Amen; Mohamed Mahmoud; Ola Hassanin; Mostafa Saif-Edin
Journal:  Vet Res Commun       Date:  2018-04-04       Impact factor: 2.459

2.  Protective Efficacy of Recombinant Turkey Herpes Virus (rHVT-H5) and Inactivated H5N1 Vaccines in Commercial Mulard Ducks against the Highly Pathogenic Avian Influenza (HPAI) H5N1 Clade 2.2.1 Virus.

Authors:  Walid H Kilany; Marwa Safwat; Samy M Mohammed; Abdullah Salim; Folorunso Oludayo Fasina; Olubunmi G Fasanmi; Azhar G Shalaby; Gwenaelle Dauphin; Mohammed K Hassan; Juan Lubroth; Yilma M Jobre
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

3.  Inactivated H5 Antigens of H5N8 Protect Chickens from Lethal Infections by the Highly Pathogenic H5N8 and H5N6 Avian Influenza Viruses.

Authors:  Myongha Jin; Yunyueng Jang; Taehyun Seo; Sang Heui Seo
Journal:  J Vet Res       Date:  2018-12-31       Impact factor: 1.744

Review 4.  Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.

Authors:  Virginia Aida; Vasilis C Pliasas; Peter J Neasham; J Fletcher North; Kirklin L McWhorter; Sheniqua R Glover; Constantinos S Kyriakis
Journal:  Front Vet Sci       Date:  2021-04-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.